title: The sum of all browning in FGF21 therapeutics.
abstract: FGF21 mimetics are a promising therapeutic tool, believed to exert their anti-obesity effect partly through browning of white fat. Véniant et al. (2015) and Samms et al. (2015) present evidence arguing against fat browning as the primary mechanism causal to weight loss following FGF21-based treatment in mice.
authors.affiliation: Diabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; Department of Endocrinology, St. Vincent's Hospital, Sydney, Darlinghurst, NSW 2010, Australia. Electronic address: p.lee@garvan.org.au.
authors.forename: Paul
authors.initials: P
authors.lastname: Lee
authors.affiliation: Centre for Diabetes, Obesity and Endocrinology, Westmead Millennium Institute, Westmead, NSW 2145, Australia.
authors.forename: Michael M
authors.initials: MM
authors.lastname: Swarbrick
authors.affiliation: Diabetes and Metabolism Division, Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia; Department of Endocrinology, St. Vincent's Hospital, Sydney, Darlinghurst, NSW 2010, Australia.
authors.forename: Jerry R
authors.initials: JR
authors.lastname: Greenfield
mesh_terms: D052436:Adipose Tissue, White / Q000187:drug effects*; D000818:Animals; D019440:Anti-Obesity Agents / Q000627:therapeutic use*; D005346:Fibroblast Growth Factors / Q000627:therapeutic use*; D008297:Male; D009765:Obesity / Q000188:drug therapy*
chemical_list: D019440:Anti-Obesity Agents; D005346:Fibroblast Growth Factors